| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Postpartum Hemorrhage | 57 | 2024 | 69 | 16.770 |
Why?
|
| Pregnancy | 345 | 2024 | 1815 | 14.740 |
Why?
|
| Cesarean Section | 69 | 2024 | 86 | 13.200 |
Why?
|
| Oxytocics | 49 | 2024 | 52 | 10.230 |
Why?
|
| Pre-Eclampsia | 37 | 2023 | 56 | 9.990 |
Why?
|
| Female | 373 | 2024 | 8751 | 9.390 |
Why?
|
| Delivery, Obstetric | 60 | 2024 | 78 | 9.060 |
Why?
|
| Misoprostol | 44 | 2023 | 45 | 8.380 |
Why?
|
| Breech Presentation | 31 | 2024 | 31 | 7.460 |
Why?
|
| Humans | 379 | 2024 | 14077 | 7.450 |
Why?
|
| Randomized Controlled Trials as Topic | 106 | 2024 | 237 | 7.120 |
Why?
|
| Calcium, Dietary | 19 | 2023 | 25 | 6.230 |
Why?
|
| Contraceptive Agents, Female | 11 | 2024 | 47 | 5.080 |
Why?
|
| Labor, Obstetric | 32 | 2023 | 44 | 5.060 |
Why?
|
| Dietary Supplements | 23 | 2023 | 40 | 4.540 |
Why?
|
| Obstetric Labor Complications | 21 | 2024 | 25 | 4.490 |
Why?
|
| Labor, Induced | 22 | 2021 | 24 | 4.440 |
Why?
|
| Pregnancy Complications, Cardiovascular | 16 | 2019 | 30 | 4.420 |
Why?
|
| Intrauterine Devices, Copper | 9 | 2024 | 20 | 4.400 |
Why?
|
| Antifibrinolytic Agents | 7 | 2022 | 7 | 4.360 |
Why?
|
| Medroxyprogesterone Acetate | 13 | 2024 | 44 | 4.330 |
Why?
|
| Tranexamic Acid | 10 | 2024 | 13 | 4.270 |
Why?
|
| Fetal Distress | 16 | 2018 | 16 | 4.090 |
Why?
|
| Labor Stage, Second | 11 | 2024 | 13 | 4.030 |
Why?
|
| Calcium | 15 | 2023 | 49 | 3.930 |
Why?
|
| Premature Birth | 13 | 2024 | 76 | 3.850 |
Why?
|
| Version, Fetal | 22 | 2015 | 22 | 3.840 |
Why?
|
| Amnion | 18 | 2014 | 19 | 3.610 |
Why?
|
| Oxytocin | 22 | 2024 | 24 | 3.550 |
Why?
|
| Prenatal Care | 11 | 2023 | 141 | 3.490 |
Why?
|
| Labor Stage, Third | 24 | 2021 | 24 | 3.350 |
Why?
|
| Uterine Balloon Tamponade | 6 | 2023 | 8 | 3.130 |
Why?
|
| Hypertension | 17 | 2019 | 397 | 2.710 |
Why?
|
| Meconium | 14 | 2014 | 20 | 2.660 |
Why?
|
| Developing Countries | 13 | 2024 | 385 | 2.630 |
Why?
|
| Parturition | 9 | 2023 | 30 | 2.600 |
Why?
|
| Dystocia | 7 | 2024 | 10 | 2.430 |
Why?
|
| Pregnancy Outcome | 25 | 2024 | 112 | 2.410 |
Why?
|
| Posture | 14 | 2024 | 16 | 2.310 |
Why?
|
| Levonorgestrel | 6 | 2024 | 17 | 2.310 |
Why?
|
| Adult | 81 | 2024 | 5664 | 2.280 |
Why?
|
| Cervical Ripening | 8 | 2021 | 8 | 2.190 |
Why?
|
| Heart Rate, Fetal | 18 | 2020 | 19 | 2.170 |
Why?
|
| Fetal Growth Retardation | 14 | 2003 | 14 | 2.140 |
Why?
|
| Injections | 15 | 2018 | 30 | 2.120 |
Why?
|
| Maternal Mortality | 13 | 2021 | 54 | 2.020 |
Why?
|
| Amniotic Fluid | 7 | 2016 | 13 | 1.980 |
Why?
|
| Meconium Aspiration Syndrome | 9 | 2014 | 13 | 1.930 |
Why?
|
| Norethindrone | 6 | 2024 | 26 | 1.890 |
Why?
|
| Progestins | 7 | 2024 | 14 | 1.820 |
Why?
|
| Infant, Newborn | 43 | 2023 | 1410 | 1.820 |
Why?
|
| Pregnancy Complications | 11 | 2015 | 53 | 1.790 |
Why?
|
| Tocolysis | 8 | 2018 | 8 | 1.770 |
Why?
|
| Anesthesia, Spinal | 2 | 2022 | 3 | 1.690 |
Why?
|
| Placenta | 9 | 2023 | 43 | 1.670 |
Why?
|
| Uterus | 8 | 2017 | 20 | 1.610 |
Why?
|
| Contraception | 6 | 2024 | 90 | 1.580 |
Why?
|
| Fluid Therapy | 9 | 2016 | 24 | 1.530 |
Why?
|
| Traction | 5 | 2015 | 6 | 1.510 |
Why?
|
| Massage | 6 | 2017 | 6 | 1.480 |
Why?
|
| Food, Fortified | 6 | 2022 | 11 | 1.390 |
Why?
|
| HIV Infections | 16 | 2024 | 4946 | 1.390 |
Why?
|
| Placenta Previa | 3 | 2021 | 3 | 1.390 |
Why?
|
| Tocolytic Agents | 7 | 2018 | 7 | 1.360 |
Why?
|
| Lower Body Negative Pressure | 6 | 2012 | 6 | 1.350 |
Why?
|
| World Health Organization | 9 | 2021 | 134 | 1.340 |
Why?
|
| Young Adult | 20 | 2024 | 2357 | 1.330 |
Why?
|
| Perinatal Death | 4 | 2023 | 32 | 1.330 |
Why?
|
| Fetal Membranes, Premature Rupture | 7 | 2015 | 7 | 1.280 |
Why?
|
| Labor Stage, First | 5 | 2024 | 8 | 1.280 |
Why?
|
| Sodium Chloride | 9 | 2014 | 16 | 1.220 |
Why?
|
| Umbilical Cord | 6 | 2015 | 7 | 1.210 |
Why?
|
| Oxygen Inhalation Therapy | 5 | 2012 | 13 | 1.200 |
Why?
|
| Oligohydramnios | 6 | 2012 | 6 | 1.190 |
Why?
|
| Mothers | 6 | 2024 | 190 | 1.180 |
Why?
|
| Stillbirth | 8 | 2023 | 81 | 1.150 |
Why?
|
| Blood Pressure | 7 | 2020 | 312 | 1.140 |
Why?
|
| Fetal Monitoring | 11 | 2015 | 13 | 1.130 |
Why?
|
| Midwifery | 9 | 2024 | 12 | 1.120 |
Why?
|
| Double-Blind Method | 17 | 2020 | 263 | 1.110 |
Why?
|
| Patient Positioning | 7 | 2017 | 7 | 1.100 |
Why?
|
| Term Birth | 4 | 2015 | 5 | 1.100 |
Why?
|
| Treatment Outcome | 17 | 2023 | 867 | 1.070 |
Why?
|
| South Africa | 34 | 2023 | 7312 | 1.020 |
Why?
|
| Antibiotic Prophylaxis | 6 | 2015 | 21 | 1.020 |
Why?
|
| Contraception Behavior | 2 | 2016 | 54 | 1.010 |
Why?
|
| Uterine Contraction | 7 | 2018 | 7 | 0.980 |
Why?
|
| Perinatal Care | 8 | 2021 | 20 | 0.980 |
Why?
|
| Peritoneum | 3 | 2014 | 5 | 0.940 |
Why?
|
| Perinatal Mortality | 6 | 2015 | 11 | 0.930 |
Why?
|
| Acne Vulgaris | 1 | 2024 | 4 | 0.930 |
Why?
|
| Tourniquets | 2 | 2021 | 2 | 0.930 |
Why?
|
| Pregnancy, Twin | 2 | 2015 | 2 | 0.930 |
Why?
|
| Anesthetics, Local | 3 | 2022 | 6 | 0.910 |
Why?
|
| Hypertension, Pregnancy-Induced | 3 | 2022 | 5 | 0.900 |
Why?
|
| Labor Presentation | 5 | 2009 | 6 | 0.900 |
Why?
|
| Fetal Movement | 5 | 2015 | 5 | 0.900 |
Why?
|
| Depression | 4 | 2021 | 117 | 0.880 |
Why?
|
| Adolescent | 22 | 2024 | 2858 | 0.880 |
Why?
|
| Hemostatics | 1 | 2023 | 17 | 0.880 |
Why?
|
| Obstetrics | 6 | 2021 | 10 | 0.870 |
Why?
|
| Preconception Care | 2 | 2020 | 11 | 0.870 |
Why?
|
| Ergonovine | 7 | 2021 | 7 | 0.850 |
Why?
|
| Fetal Diseases | 5 | 2012 | 7 | 0.830 |
Why?
|
| Uterine Hemorrhage | 5 | 2021 | 5 | 0.820 |
Why?
|
| Sexual Behavior | 2 | 2024 | 313 | 0.810 |
Why?
|
| Uterine Rupture | 2 | 2016 | 3 | 0.810 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2020 | 21 | 0.800 |
Why?
|
| Symphysiotomy | 2 | 2012 | 2 | 0.790 |
Why?
|
| Cephalopelvic Disproportion | 2 | 2012 | 2 | 0.790 |
Why?
|
| Piracetam | 3 | 2012 | 3 | 0.790 |
Why?
|
| Neuroprotective Agents | 3 | 2012 | 15 | 0.780 |
Why?
|
| Breast Feeding | 8 | 2018 | 119 | 0.780 |
Why?
|
| Endometritis | 8 | 2016 | 8 | 0.760 |
Why?
|
| Elective Surgical Procedures | 4 | 2015 | 9 | 0.750 |
Why?
|
| Maternal Death | 2 | 2023 | 25 | 0.740 |
Why?
|
| Proteinuria | 3 | 2009 | 14 | 0.730 |
Why?
|
| Chorioamnionitis | 2 | 2016 | 10 | 0.720 |
Why?
|
| Aspirin | 1 | 2020 | 15 | 0.710 |
Why?
|
| Ultrasonography, Prenatal | 4 | 2009 | 24 | 0.710 |
Why?
|
| Pain, Postoperative | 2 | 2010 | 6 | 0.690 |
Why?
|
| Anesthesia, Obstetrical | 5 | 2013 | 5 | 0.680 |
Why?
|
| Hypotension | 5 | 2013 | 7 | 0.670 |
Why?
|
| Anesthesia, Epidural | 4 | 2017 | 4 | 0.660 |
Why?
|
| Abruptio Placentae | 3 | 2016 | 3 | 0.650 |
Why?
|
| Abortion, Induced | 7 | 2011 | 16 | 0.650 |
Why?
|
| Time Factors | 18 | 2017 | 503 | 0.650 |
Why?
|
| Catheterization | 2 | 2016 | 6 | 0.590 |
Why?
|
| Analgesia, Obstetrical | 6 | 2015 | 7 | 0.580 |
Why?
|
| Shoulder | 4 | 2015 | 4 | 0.580 |
Why?
|
| Isotonic Solutions | 5 | 2016 | 5 | 0.580 |
Why?
|
| Hospitals, Maternity | 2 | 2014 | 4 | 0.570 |
Why?
|
| Fetal Death | 5 | 2009 | 6 | 0.570 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 3 | 2005 | 3 | 0.570 |
Why?
|
| Extraction, Obstetrical | 3 | 2015 | 3 | 0.560 |
Why?
|
| Network Meta-Analysis | 4 | 2023 | 8 | 0.560 |
Why?
|
| Infant | 9 | 2024 | 2145 | 0.550 |
Why?
|
| Postoperative Hemorrhage | 1 | 2016 | 2 | 0.540 |
Why?
|
| Zimbabwe | 6 | 2020 | 115 | 0.540 |
Why?
|
| Abortion, Legal | 1 | 2016 | 7 | 0.540 |
Why?
|
| Administration, Intravaginal | 9 | 2014 | 50 | 0.530 |
Why?
|
| Argentina | 5 | 2020 | 11 | 0.530 |
Why?
|
| Bone Density Conservation Agents | 1 | 2015 | 3 | 0.500 |
Why?
|
| Fever | 6 | 2018 | 25 | 0.500 |
Why?
|
| Abnormalities, Drug-Induced | 2 | 2009 | 2 | 0.500 |
Why?
|
| Blood Pressure Determination | 1 | 2015 | 27 | 0.490 |
Why?
|
| Delivery Rooms | 1 | 2014 | 3 | 0.490 |
Why?
|
| HIV-1 | 4 | 2022 | 1239 | 0.490 |
Why?
|
| Testosterone | 3 | 2024 | 14 | 0.480 |
Why?
|
| Abdominal Wound Closure Techniques | 1 | 2014 | 1 | 0.480 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2024 | 7 | 0.470 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2014 | 6 | 0.470 |
Why?
|
| Postpartum Period | 8 | 2023 | 78 | 0.470 |
Why?
|
| Pregnancy Trimester, Third | 12 | 2015 | 30 | 0.460 |
Why?
|
| Risk Factors | 15 | 2019 | 1431 | 0.450 |
Why?
|
| Prostaglandins | 7 | 2018 | 7 | 0.450 |
Why?
|
| Anesthesia, Local | 2 | 2010 | 2 | 0.440 |
Why?
|
| Adrenergic beta-Agonists | 4 | 2001 | 25 | 0.440 |
Why?
|
| Developed Countries | 2 | 2020 | 23 | 0.430 |
Why?
|
| Fetal Development | 2 | 2012 | 19 | 0.430 |
Why?
|
| Gestational Age | 8 | 2024 | 78 | 0.430 |
Why?
|
| Feasibility Studies | 4 | 2023 | 95 | 0.430 |
Why?
|
| Fetus | 3 | 2009 | 8 | 0.420 |
Why?
|
| Vacuum Extraction, Obstetrical | 3 | 2010 | 3 | 0.420 |
Why?
|
| Primary Health Care | 1 | 2014 | 228 | 0.420 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2015 | 467 | 0.420 |
Why?
|
| Evidence-Based Medicine | 4 | 2016 | 34 | 0.410 |
Why?
|
| Suture Techniques | 3 | 2014 | 6 | 0.400 |
Why?
|
| Abdominal Wall | 2 | 2013 | 5 | 0.390 |
Why?
|
| Nutritional Support | 2 | 2003 | 5 | 0.390 |
Why?
|
| Hormones | 2 | 2003 | 9 | 0.390 |
Why?
|
| Pregnancy Complications, Hematologic | 2 | 2008 | 9 | 0.390 |
Why?
|
| Pressure | 4 | 2017 | 6 | 0.390 |
Why?
|
| Urinary Catheterization | 2 | 2021 | 3 | 0.380 |
Why?
|
| Child Development | 1 | 2012 | 89 | 0.380 |
Why?
|
| Suction | 3 | 2020 | 10 | 0.370 |
Why?
|
| Drug Implants | 2 | 2024 | 21 | 0.370 |
Why?
|
| Pilot Projects | 9 | 2024 | 168 | 0.360 |
Why?
|
| Injections, Intramuscular | 5 | 2024 | 30 | 0.360 |
Why?
|
| Nutrition Policy | 2 | 2020 | 19 | 0.360 |
Why?
|
| Administration, Oral | 10 | 2012 | 113 | 0.350 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2017 | 507 | 0.350 |
Why?
|
| Fetal Heart | 6 | 2012 | 6 | 0.350 |
Why?
|
| Clozapine | 1 | 2009 | 1 | 0.340 |
Why?
|
| Nerve Block | 1 | 2009 | 1 | 0.340 |
Why?
|
| Abdomen | 1 | 2009 | 2 | 0.340 |
Why?
|
| Antipsychotic Agents | 1 | 2009 | 10 | 0.340 |
Why?
|
| Infusions, Parenteral | 3 | 2014 | 4 | 0.340 |
Why?
|
| Micronutrients | 2 | 2020 | 11 | 0.330 |
Why?
|
| Hexoprenaline | 4 | 2018 | 4 | 0.330 |
Why?
|
| Botswana | 3 | 2024 | 24 | 0.330 |
Why?
|
| Tanzania | 3 | 2024 | 84 | 0.330 |
Why?
|
| Delphi Technique | 2 | 2024 | 28 | 0.330 |
Why?
|
| Risk Assessment | 6 | 2018 | 217 | 0.330 |
Why?
|
| Early Diagnosis | 3 | 2024 | 80 | 0.330 |
Why?
|
| Calcium Channel Blockers | 3 | 2015 | 14 | 0.320 |
Why?
|
| Cervix Uteri | 3 | 2020 | 21 | 0.320 |
Why?
|
| Puerperal Disorders | 4 | 2001 | 9 | 0.320 |
Why?
|
| Prospective Studies | 12 | 2022 | 1131 | 0.320 |
Why?
|
| Uric Acid | 2 | 2008 | 6 | 0.310 |
Why?
|
| Shivering | 3 | 2012 | 3 | 0.310 |
Why?
|
| Nitroglycerin | 3 | 2018 | 3 | 0.310 |
Why?
|
| Vitamins | 2 | 2018 | 23 | 0.310 |
Why?
|
| Walking | 3 | 2013 | 14 | 0.310 |
Why?
|
| Dinoprostone | 3 | 2003 | 6 | 0.300 |
Why?
|
| Cost-Benefit Analysis | 3 | 2024 | 235 | 0.300 |
Why?
|
| Incidence | 4 | 2023 | 655 | 0.300 |
Why?
|
| Acoustic Stimulation | 2 | 1998 | 2 | 0.300 |
Why?
|
| Specimen Handling | 1 | 2008 | 103 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 123 | 0.290 |
Why?
|
| Infant Mortality | 5 | 2023 | 92 | 0.280 |
Why?
|
| Catecholamines | 3 | 1996 | 6 | 0.280 |
Why?
|
| Nutritional Status | 2 | 2018 | 75 | 0.280 |
Why?
|
| Cerebral Hemorrhage | 3 | 1993 | 6 | 0.280 |
Why?
|
| Anti-HIV Agents | 3 | 2022 | 1275 | 0.270 |
Why?
|
| Administration, Sublingual | 4 | 2012 | 4 | 0.270 |
Why?
|
| Placental Insufficiency | 2 | 2000 | 2 | 0.270 |
Why?
|
| Capillary Fragility | 1 | 2006 | 1 | 0.270 |
Why?
|
| Edema | 1 | 2006 | 7 | 0.270 |
Why?
|
| Varicose Veins | 1 | 2006 | 4 | 0.270 |
Why?
|
| Apgar Score | 3 | 2017 | 8 | 0.270 |
Why?
|
| Episiotomy | 6 | 2020 | 6 | 0.270 |
Why?
|
| Global Health | 4 | 2019 | 183 | 0.260 |
Why?
|
| Length of Stay | 2 | 2016 | 43 | 0.260 |
Why?
|
| Folic Acid | 2 | 2022 | 12 | 0.250 |
Why?
|
| Vagina | 6 | 2021 | 91 | 0.250 |
Why?
|
| Perineum | 4 | 2020 | 5 | 0.250 |
Why?
|
| Nigeria | 4 | 2023 | 40 | 0.250 |
Why?
|
| Clinical Trials as Topic | 3 | 2023 | 112 | 0.240 |
Why?
|
| Hemostatic Techniques | 2 | 2021 | 2 | 0.240 |
Why?
|
| Estradiol | 2 | 2024 | 18 | 0.240 |
Why?
|
| Androgens | 1 | 2024 | 5 | 0.230 |
Why?
|
| Birth Weight | 3 | 2020 | 78 | 0.230 |
Why?
|
| Consensus | 1 | 2024 | 59 | 0.230 |
Why?
|
| Nutritional Requirements | 2 | 2020 | 6 | 0.230 |
Why?
|
| Depression, Postpartum | 3 | 1998 | 22 | 0.230 |
Why?
|
| Drug Therapy, Combination | 10 | 2020 | 271 | 0.230 |
Why?
|
| Maternal Health Services | 1 | 2004 | 51 | 0.230 |
Why?
|
| Milk, Human | 3 | 1992 | 22 | 0.230 |
Why?
|
| Plasma Substitutes | 2 | 2001 | 2 | 0.220 |
Why?
|
| Clinical Protocols | 4 | 2016 | 24 | 0.220 |
Why?
|
| Patient Care Bundles | 1 | 2023 | 4 | 0.220 |
Why?
|
| Child | 4 | 2023 | 2180 | 0.210 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 3 | 2014 | 3 | 0.210 |
Why?
|
| Medication Errors | 1 | 2022 | 4 | 0.210 |
Why?
|
| Jaundice, Neonatal | 1 | 2022 | 2 | 0.210 |
Why?
|
| Neural Tube Defects | 1 | 2022 | 6 | 0.210 |
Why?
|
| Magnesium Sulfate | 2 | 2000 | 3 | 0.210 |
Why?
|
| Research Design | 4 | 2017 | 123 | 0.210 |
Why?
|
| Diet | 3 | 2020 | 108 | 0.210 |
Why?
|
| Brain Diseases | 1 | 2022 | 24 | 0.210 |
Why?
|
| Terbutaline | 2 | 2018 | 2 | 0.200 |
Why?
|
| Myometrium | 1 | 2002 | 1 | 0.200 |
Why?
|
| Random Allocation | 3 | 2019 | 23 | 0.200 |
Why?
|
| Ileum | 1 | 2002 | 3 | 0.200 |
Why?
|
| Postoperative Care | 1 | 2002 | 2 | 0.200 |
Why?
|
| Abortion, Habitual | 3 | 1993 | 4 | 0.200 |
Why?
|
| Food | 1 | 2002 | 11 | 0.200 |
Why?
|
| Catheters | 1 | 2021 | 1 | 0.200 |
Why?
|
| Pelvimetry | 2 | 2012 | 2 | 0.200 |
Why?
|
| Birth Injuries | 4 | 2015 | 4 | 0.200 |
Why?
|
| Urinary Catheters | 1 | 2021 | 1 | 0.200 |
Why?
|
| Anticonvulsants | 2 | 1999 | 13 | 0.200 |
Why?
|
| Self Concept | 3 | 1993 | 13 | 0.200 |
Why?
|
| Confidence Intervals | 3 | 2020 | 26 | 0.200 |
Why?
|
| History, 20th Century | 2 | 2020 | 22 | 0.200 |
Why?
|
| Shock | 1 | 2001 | 4 | 0.200 |
Why?
|
| Constriction | 4 | 2015 | 6 | 0.190 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 367 | 0.190 |
Why?
|
| Obstetric Labor, Premature | 3 | 2003 | 6 | 0.190 |
Why?
|
| Physicians, Family | 1 | 2001 | 4 | 0.190 |
Why?
|
| Gynecology | 1 | 2021 | 2 | 0.190 |
Why?
|
| Internship and Residency | 1 | 2021 | 6 | 0.190 |
Why?
|
| Data Collection | 3 | 2009 | 86 | 0.190 |
Why?
|
| Patient Selection | 2 | 2018 | 40 | 0.190 |
Why?
|
| Uterine Artery Embolization | 2 | 2021 | 2 | 0.190 |
Why?
|
| Water | 2 | 2020 | 22 | 0.190 |
Why?
|
| Patient Education as Topic | 3 | 2012 | 48 | 0.190 |
Why?
|
| Hysterectomy | 2 | 2021 | 9 | 0.190 |
Why?
|
| Antioxidants | 2 | 2017 | 25 | 0.180 |
Why?
|
| Blood Transfusion | 2 | 2020 | 11 | 0.180 |
Why?
|
| History, 19th Century | 1 | 2020 | 3 | 0.180 |
Why?
|
| Electrodes | 3 | 1996 | 7 | 0.180 |
Why?
|
| Decompression | 2 | 1990 | 2 | 0.180 |
Why?
|
| Surgical Wound Infection | 3 | 2010 | 13 | 0.180 |
Why?
|
| Inappropriate Prescribing | 1 | 2020 | 1 | 0.180 |
Why?
|
| Heart Rate | 4 | 1983 | 32 | 0.180 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2020 | 13 | 0.180 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2020 | 12 | 0.180 |
Why?
|
| Infant, Premature | 1 | 2020 | 52 | 0.180 |
Why?
|
| Bed Rest | 1 | 2000 | 1 | 0.180 |
Why?
|
| Plasma Volume | 1 | 2000 | 1 | 0.180 |
Why?
|
| Electric Stimulation Therapy | 1 | 2000 | 2 | 0.180 |
Why?
|
| Weight Gain | 1 | 2020 | 73 | 0.170 |
Why?
|
| HIV Seropositivity | 1 | 2022 | 263 | 0.170 |
Why?
|
| Anthropometry | 1 | 2000 | 101 | 0.170 |
Why?
|
| Attitude of Health Personnel | 1 | 2001 | 102 | 0.170 |
Why?
|
| Public Health | 1 | 2020 | 122 | 0.170 |
Why?
|
| Infant, Low Birth Weight | 2 | 2023 | 33 | 0.170 |
Why?
|
| Obesity | 2 | 2023 | 356 | 0.170 |
Why?
|
| Disease Progression | 3 | 2020 | 154 | 0.170 |
Why?
|
| Sexual Partners | 2 | 2017 | 211 | 0.160 |
Why?
|
| Placenta, Retained | 2 | 2020 | 2 | 0.160 |
Why?
|
| Linoleic Acid | 1 | 2018 | 1 | 0.160 |
Why?
|
| Cells, Cultured | 1 | 2018 | 79 | 0.160 |
Why?
|
| Beverages | 1 | 1999 | 42 | 0.160 |
Why?
|
| Respiration | 2 | 1997 | 2 | 0.160 |
Why?
|
| Vasotocin | 1 | 2018 | 1 | 0.160 |
Why?
|
| Fenoterol | 1 | 2018 | 3 | 0.160 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2018 | 4 | 0.160 |
Why?
|
| Vitamin D | 1 | 2018 | 39 | 0.160 |
Why?
|
| Twins | 1 | 1998 | 1 | 0.150 |
Why?
|
| Psychology, Child | 1 | 1998 | 3 | 0.150 |
Why?
|
| Leg | 1 | 1998 | 21 | 0.150 |
Why?
|
| Dysmenorrhea | 1 | 2017 | 2 | 0.150 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2017 | 2 | 0.150 |
Why?
|
| Pregnancy Trimester, First | 5 | 2011 | 10 | 0.150 |
Why?
|
| Calcium Carbonate | 1 | 2017 | 3 | 0.150 |
Why?
|
| Hospitalization | 2 | 2000 | 392 | 0.150 |
Why?
|
| Selenium | 1 | 2017 | 3 | 0.150 |
Why?
|
| Acetylcysteine | 1 | 2017 | 4 | 0.150 |
Why?
|
| Zinc | 1 | 2017 | 10 | 0.150 |
Why?
|
| Copper | 1 | 2017 | 15 | 0.150 |
Why?
|
| Long-Acting Reversible Contraception | 1 | 2017 | 11 | 0.150 |
Why?
|
| Vibration | 2 | 2015 | 7 | 0.150 |
Why?
|
| Behavior | 1 | 2017 | 5 | 0.150 |
Why?
|
| Manganese | 1 | 2017 | 11 | 0.150 |
Why?
|
| Risk | 4 | 2023 | 87 | 0.150 |
Why?
|
| Self Disclosure | 1 | 2017 | 8 | 0.150 |
Why?
|
| Abortion, Spontaneous | 1 | 2017 | 11 | 0.150 |
Why?
|
| Kenya | 3 | 2023 | 173 | 0.150 |
Why?
|
| Personal Autonomy | 1 | 2017 | 5 | 0.150 |
Why?
|
| Umbilical Veins | 2 | 1994 | 3 | 0.150 |
Why?
|
| Fetal Blood | 2 | 1996 | 27 | 0.150 |
Why?
|
| Demography | 1 | 2017 | 105 | 0.140 |
Why?
|
| Chickenpox | 1 | 1996 | 2 | 0.140 |
Why?
|
| Data Interpretation, Statistical | 2 | 2015 | 22 | 0.140 |
Why?
|
| Retrospective Studies | 5 | 2014 | 767 | 0.140 |
Why?
|
| Abortifacient Agents | 3 | 2011 | 4 | 0.140 |
Why?
|
| Patient Dropouts | 2 | 2017 | 18 | 0.140 |
Why?
|
| Injections, Intravenous | 3 | 2015 | 11 | 0.140 |
Why?
|
| Spheniscidae | 1 | 2016 | 1 | 0.140 |
Why?
|
| Food Analysis | 1 | 2016 | 3 | 0.140 |
Why?
|
| Birth Intervals | 1 | 2016 | 3 | 0.140 |
Why?
|
| Gravity Suits | 1 | 2016 | 1 | 0.140 |
Why?
|
| Urinary Tract Infections | 2 | 2010 | 12 | 0.140 |
Why?
|
| Home Childbirth | 1 | 2016 | 5 | 0.140 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2016 | 2 | 0.140 |
Why?
|
| Postoperative Period | 1 | 2016 | 4 | 0.140 |
Why?
|
| Back Pain | 1 | 2016 | 4 | 0.140 |
Why?
|
| Abdominal Pain | 1 | 2016 | 7 | 0.140 |
Why?
|
| Pregnancy Rate | 1 | 2016 | 8 | 0.130 |
Why?
|
| Animals | 6 | 2022 | 1063 | 0.130 |
Why?
|
| Viral Load | 1 | 2020 | 808 | 0.130 |
Why?
|
| Health Facilities | 1 | 2016 | 39 | 0.130 |
Why?
|
| Health Promotion | 2 | 2007 | 108 | 0.130 |
Why?
|
| Arousal | 1 | 1995 | 1 | 0.130 |
Why?
|
| Affect | 1 | 1995 | 4 | 0.130 |
Why?
|
| Hydrocortisone | 1 | 1995 | 10 | 0.130 |
Why?
|
| Feeding Behavior | 1 | 2016 | 59 | 0.130 |
Why?
|
| Cardiotocography | 4 | 2009 | 5 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 124 | 0.130 |
Why?
|
| Lost to Follow-Up | 1 | 2016 | 62 | 0.130 |
Why?
|
| beta-Endorphin | 1 | 1995 | 1 | 0.130 |
Why?
|
| Healthcare Financing | 1 | 2015 | 5 | 0.130 |
Why?
|
| Brachial Plexus Neuropathies | 1 | 2015 | 1 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2015 | 32 | 0.130 |
Why?
|
| Uganda | 2 | 2018 | 194 | 0.130 |
Why?
|
| Rotation | 1 | 2015 | 5 | 0.130 |
Why?
|
| Axilla | 1 | 2015 | 3 | 0.130 |
Why?
|
| Streptococcal Infections | 1 | 1997 | 179 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2015 | 132 | 0.120 |
Why?
|
| Hospitals | 1 | 1995 | 102 | 0.120 |
Why?
|
| Medical Audit | 1 | 2014 | 26 | 0.120 |
Why?
|
| Tissue Adhesions | 1 | 2014 | 1 | 0.120 |
Why?
|
| Peritoneal Diseases | 1 | 2014 | 2 | 0.120 |
Why?
|
| Operative Time | 1 | 2014 | 4 | 0.120 |
Why?
|
| Prevalence | 4 | 2018 | 1149 | 0.120 |
Why?
|
| Drug Administration Schedule | 4 | 2015 | 153 | 0.120 |
Why?
|
| Fetal Weight | 4 | 2015 | 5 | 0.120 |
Why?
|
| Equipment Design | 5 | 1997 | 27 | 0.120 |
Why?
|
| Treatment Failure | 2 | 2009 | 175 | 0.120 |
Why?
|
| Social Support | 2 | 1993 | 76 | 0.120 |
Why?
|
| Estrogens | 1 | 2014 | 6 | 0.120 |
Why?
|
| Domperidone | 2 | 1985 | 2 | 0.120 |
Why?
|
| Abortion, Therapeutic | 1 | 1994 | 1 | 0.120 |
Why?
|
| Down Syndrome | 1 | 1994 | 1 | 0.120 |
Why?
|
| Diseases in Twins | 1 | 1994 | 2 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 274 | 0.120 |
Why?
|
| Pregnancy, High-Risk | 4 | 2018 | 5 | 0.120 |
Why?
|
| CD-ROM | 1 | 2013 | 1 | 0.110 |
Why?
|
| Libraries, Digital | 1 | 2013 | 1 | 0.110 |
Why?
|
| Supine Position | 4 | 2017 | 5 | 0.110 |
Why?
|
| Information Dissemination | 1 | 2013 | 7 | 0.110 |
Why?
|
| Brassica | 1 | 1993 | 1 | 0.110 |
Why?
|
| Lactation Disorders | 1 | 1993 | 1 | 0.110 |
Why?
|
| Obstetric Nursing | 5 | 2013 | 5 | 0.110 |
Why?
|
| Egypt | 2 | 2010 | 4 | 0.110 |
Why?
|
| Reproductive Health | 1 | 2013 | 51 | 0.110 |
Why?
|
| Lactation | 3 | 2018 | 12 | 0.110 |
Why?
|
| Urban Health | 3 | 2005 | 78 | 0.110 |
Why?
|
| Chorionic Gonadotropin | 2 | 1992 | 2 | 0.110 |
Why?
|
| Pregnancy, Ectopic | 2 | 1992 | 2 | 0.110 |
Why?
|
| Emergencies | 2 | 2015 | 16 | 0.110 |
Why?
|
| Women's Health | 1 | 2013 | 41 | 0.110 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2015 | 171 | 0.110 |
Why?
|
| Pubic Symphysis | 1 | 2012 | 1 | 0.110 |
Why?
|
| Pregnancy Trimester, Second | 4 | 2015 | 8 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 230 | 0.100 |
Why?
|
| Estriol | 1 | 2012 | 1 | 0.100 |
Why?
|
| Cystadenoma | 1 | 1992 | 1 | 0.100 |
Why?
|
| Leukocytes | 2 | 1993 | 14 | 0.100 |
Why?
|
| Ovarian Neoplasms | 1 | 1992 | 15 | 0.100 |
Why?
|
| Community Health Services | 1 | 2012 | 58 | 0.100 |
Why?
|
| Constriction, Pathologic | 1 | 2012 | 2 | 0.100 |
Why?
|
| Loperamide | 1 | 1992 | 1 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2002 | 247 | 0.100 |
Why?
|
| Platelet Count | 2 | 2010 | 14 | 0.100 |
Why?
|
| Placental Function Tests | 1 | 1991 | 1 | 0.100 |
Why?
|
| Umbilical Arteries | 1 | 1991 | 2 | 0.100 |
Why?
|
| Pelvis | 1 | 1991 | 5 | 0.100 |
Why?
|
| Drug Administration Routes | 2 | 2005 | 8 | 0.100 |
Why?
|
| Pulmonary Edema | 1 | 1991 | 2 | 0.100 |
Why?
|
| Parent-Child Relations | 1 | 1991 | 16 | 0.100 |
Why?
|
| Complement C4 | 1 | 1991 | 1 | 0.090 |
Why?
|
| Blood Proteins | 1 | 1991 | 2 | 0.090 |
Why?
|
| Asphyxia Neonatorum | 1 | 2011 | 11 | 0.090 |
Why?
|
| Homeopathy | 1 | 1990 | 1 | 0.090 |
Why?
|
| Obstetrical Forceps | 1 | 2010 | 1 | 0.090 |
Why?
|
| HELLP Syndrome | 1 | 2010 | 3 | 0.090 |
Why?
|
| Body Image | 1 | 1990 | 17 | 0.090 |
Why?
|
| Aminobenzoates | 1 | 2010 | 1 | 0.090 |
Why?
|
| Ritodrine | 2 | 2001 | 2 | 0.090 |
Why?
|
| Plant Extracts | 1 | 1990 | 28 | 0.090 |
Why?
|
| Hemorrhage | 2 | 2017 | 70 | 0.090 |
Why?
|
| Surveys and Questionnaires | 4 | 2017 | 532 | 0.090 |
Why?
|
| Suicide, Attempted | 1 | 2009 | 3 | 0.090 |
Why?
|
| Cohort Studies | 4 | 2018 | 939 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2009 | 17 | 0.080 |
Why?
|
| Body Mass Index | 2 | 2023 | 312 | 0.080 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2009 | 19 | 0.080 |
Why?
|
| Registries | 1 | 2009 | 89 | 0.080 |
Why?
|
| Peptide Fragments | 1 | 1989 | 36 | 0.080 |
Why?
|
| Vomiting | 2 | 2018 | 4 | 0.080 |
Why?
|
| Recurrence | 3 | 2017 | 27 | 0.080 |
Why?
|
| Blood Loss, Surgical | 1 | 2008 | 5 | 0.080 |
Why?
|
| Betamethasone | 2 | 2010 | 3 | 0.080 |
Why?
|
| Male | 8 | 2018 | 6489 | 0.080 |
Why?
|
| London | 2 | 2018 | 8 | 0.080 |
Why?
|
| Socioeconomic Factors | 1 | 2009 | 405 | 0.070 |
Why?
|
| Biomarkers | 1 | 2009 | 322 | 0.070 |
Why?
|
| Guideline Adherence | 2 | 2007 | 42 | 0.070 |
Why?
|
| Health Priorities | 1 | 2008 | 62 | 0.070 |
Why?
|
| Surgical Wound Dehiscence | 1 | 1987 | 1 | 0.070 |
Why?
|
| Child, Preschool | 1 | 2012 | 1675 | 0.070 |
Why?
|
| Drug Stability | 2 | 2018 | 13 | 0.070 |
Why?
|
| Organizational Policy | 1 | 2007 | 2 | 0.070 |
Why?
|
| Volunteers | 1 | 2007 | 3 | 0.070 |
Why?
|
| Friends | 1 | 2007 | 6 | 0.070 |
Why?
|
| Immunization | 1 | 1987 | 63 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2005 | 32 | 0.070 |
Why?
|
| von Willebrand Diseases | 1 | 1987 | 8 | 0.070 |
Why?
|
| Dyspareunia | 1 | 1987 | 1 | 0.070 |
Why?
|
| Hospitals, Public | 1 | 2007 | 44 | 0.070 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2006 | 1 | 0.070 |
Why?
|
| Stockings, Compression | 1 | 2006 | 1 | 0.070 |
Why?
|
| Rutin | 1 | 2006 | 2 | 0.070 |
Why?
|
| Eclampsia | 2 | 2016 | 6 | 0.070 |
Why?
|
| Scalp | 3 | 1996 | 3 | 0.070 |
Why?
|
| Piperidines | 1 | 1986 | 4 | 0.070 |
Why?
|
| Embryonic and Fetal Development | 2 | 2000 | 4 | 0.070 |
Why?
|
| Brain Stem | 1 | 1985 | 5 | 0.060 |
Why?
|
| Epidemiologic Methods | 1 | 2005 | 25 | 0.060 |
Why?
|
| Cerebral Cortex | 1 | 1985 | 9 | 0.060 |
Why?
|
| Vaginosis, Bacterial | 2 | 2015 | 19 | 0.060 |
Why?
|
| Prolactin | 1 | 1985 | 4 | 0.060 |
Why?
|
| Dilatation and Curettage | 2 | 2001 | 2 | 0.060 |
Why?
|
| Vacuum Curettage | 2 | 2001 | 2 | 0.060 |
Why?
|
| Sutures | 1 | 2005 | 2 | 0.060 |
Why?
|
| Intestinal Obstruction | 1 | 1985 | 2 | 0.060 |
Why?
|
| Sigmoid Diseases | 1 | 1985 | 2 | 0.060 |
Why?
|
| Infertility, Female | 2 | 1997 | 3 | 0.060 |
Why?
|
| Trial of Labor | 1 | 2004 | 1 | 0.060 |
Why?
|
| Decision Making | 2 | 2012 | 52 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2020 | 22 | 0.060 |
Why?
|
| Rural Health | 1 | 2005 | 118 | 0.060 |
Why?
|
| Uterine Inertia | 2 | 2020 | 2 | 0.060 |
Why?
|
| Medical Laboratory Science | 1 | 2004 | 4 | 0.060 |
Why?
|
| Attitude to Health | 2 | 1995 | 56 | 0.060 |
Why?
|
| Diffusion of Innovation | 1 | 2004 | 10 | 0.060 |
Why?
|
| Evidence-Based Practice | 1 | 2023 | 4 | 0.060 |
Why?
|
| Contraceptive Agents | 1 | 2023 | 27 | 0.060 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2004 | 42 | 0.060 |
Why?
|
| In Vitro Techniques | 2 | 2002 | 54 | 0.060 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2003 | 18 | 0.060 |
Why?
|
| Diethylstilbestrol | 1 | 2003 | 1 | 0.060 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2003 | 1 | 0.060 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2023 | 10 | 0.060 |
Why?
|
| Professional-Patient Relations | 2 | 2017 | 14 | 0.050 |
Why?
|
| Abortion, Incomplete | 3 | 2011 | 5 | 0.050 |
Why?
|
| Mifepristone | 3 | 2011 | 7 | 0.050 |
Why?
|
| Tamoxifen | 3 | 2011 | 9 | 0.050 |
Why?
|
| Methotrexate | 3 | 2011 | 17 | 0.050 |
Why?
|
| Vision, Ocular | 1 | 2002 | 1 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2000 | 210 | 0.050 |
Why?
|
| Acetylcholine | 1 | 2002 | 3 | 0.050 |
Why?
|
| Muscle Contraction | 1 | 2002 | 5 | 0.050 |
Why?
|
| Biological Availability | 1 | 2022 | 43 | 0.050 |
Why?
|
| Embolism, Air | 2 | 2013 | 2 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2002 | 63 | 0.050 |
Why?
|
| Postnatal Care | 2 | 1998 | 13 | 0.050 |
Why?
|
| Intraoperative Complications | 2 | 2013 | 8 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2022 | 38 | 0.050 |
Why?
|
| Australia | 1 | 2021 | 46 | 0.050 |
Why?
|
| Rats | 1 | 2002 | 130 | 0.050 |
Why?
|
| Erythrocyte Transfusion | 1 | 2001 | 6 | 0.050 |
Why?
|
| Uterine Artery | 1 | 2021 | 1 | 0.050 |
Why?
|
| Ligation | 1 | 2021 | 2 | 0.050 |
Why?
|
| Sri Lanka | 1 | 2021 | 3 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2022 | 113 | 0.050 |
Why?
|
| Vaginal Diseases | 1 | 1981 | 4 | 0.050 |
Why?
|
| Motivation | 1 | 2021 | 56 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2001 | 13 | 0.050 |
Why?
|
| Bias | 1 | 2020 | 12 | 0.050 |
Why?
|
| Flour | 1 | 2020 | 1 | 0.050 |
Why?
|
| Triticum | 1 | 2020 | 1 | 0.050 |
Why?
|
| Oryza | 1 | 2020 | 3 | 0.050 |
Why?
|
| Curriculum | 1 | 2021 | 27 | 0.050 |
Why?
|
| Reference Values | 2 | 2002 | 64 | 0.050 |
Why?
|
| Mutation | 1 | 2022 | 299 | 0.050 |
Why?
|
| Zea mays | 1 | 2020 | 5 | 0.050 |
Why?
|
| United Kingdom | 1 | 2020 | 32 | 0.050 |
Why?
|
| Genotype | 1 | 2022 | 430 | 0.050 |
Why?
|
| Program Evaluation | 2 | 2004 | 89 | 0.050 |
Why?
|
| Drug Resistance, Viral | 1 | 2022 | 268 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 16 | 0.040 |
Why?
|
| Flunarizine | 1 | 2000 | 1 | 0.040 |
Why?
|
| Ultrasonography, Doppler | 1 | 2000 | 6 | 0.040 |
Why?
|
| Linear Models | 1 | 2000 | 82 | 0.040 |
Why?
|
| Hysterosalpingography | 2 | 1997 | 2 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 163 | 0.040 |
Why?
|
| Pericardium | 1 | 1979 | 2 | 0.040 |
Why?
|
| Public Sector | 1 | 2000 | 82 | 0.040 |
Why?
|
| Pericardial Effusion | 1 | 1979 | 6 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2002 | 16 | 0.040 |
Why?
|
| Contraceptives, Oral, Synthetic | 1 | 1998 | 2 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1998 | 25 | 0.040 |
Why?
|
| Vitamin B Complex | 1 | 2018 | 1 | 0.040 |
Why?
|
| Recommended Dietary Allowances | 1 | 2018 | 11 | 0.040 |
Why?
|
| Iron | 1 | 2018 | 32 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 3 | 1991 | 25 | 0.040 |
Why?
|
| Maternal Health | 1 | 2018 | 18 | 0.040 |
Why?
|
| Health Facility Environment | 1 | 1998 | 2 | 0.040 |
Why?
|
| Burkina Faso | 1 | 2018 | 29 | 0.040 |
Why?
|
| Vaginal Birth after Cesarean | 1 | 1998 | 3 | 0.040 |
Why?
|
| Professional Practice | 1 | 1998 | 4 | 0.040 |
Why?
|
| Patient Care Team | 1 | 1998 | 11 | 0.040 |
Why?
|
| Life Change Events | 1 | 1998 | 9 | 0.040 |
Why?
|
| Sample Size | 1 | 2017 | 4 | 0.040 |
Why?
|
| Zambia | 1 | 2018 | 112 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2020 | 654 | 0.040 |
Why?
|
| Pregnancy, Unplanned | 1 | 2017 | 19 | 0.040 |
Why?
|
| Doulas | 1 | 2017 | 1 | 0.040 |
Why?
|
| Dimethylformamide | 1 | 1997 | 3 | 0.040 |
Why?
|
| Allopurinol | 1 | 1997 | 3 | 0.040 |
Why?
|
| Drugs, Investigational | 1 | 1997 | 4 | 0.040 |
Why?
|
| Vitamin E | 1 | 1997 | 9 | 0.040 |
Why?
|
| Ascorbic Acid | 1 | 1997 | 12 | 0.040 |
Why?
|
| Cause of Death | 2 | 2009 | 206 | 0.040 |
Why?
|
| Limb Deformities, Congenital | 1 | 1996 | 2 | 0.040 |
Why?
|
| Hydrocephalus | 1 | 1996 | 2 | 0.040 |
Why?
|
| Extremities | 1 | 1996 | 5 | 0.040 |
Why?
|
| Cardiomyopathies | 1 | 1996 | 14 | 0.040 |
Why?
|
| Calcinosis | 1 | 1996 | 11 | 0.040 |
Why?
|
| Lung Diseases | 1 | 1996 | 29 | 0.040 |
Why?
|
| Prognosis | 2 | 1998 | 197 | 0.030 |
Why?
|
| Gastrointestinal Contents | 1 | 2016 | 1 | 0.030 |
Why?
|
| Food Chain | 1 | 2016 | 1 | 0.030 |
Why?
|
| Endangered Species | 1 | 2016 | 1 | 0.030 |
Why?
|
| Carbon Isotopes | 1 | 2016 | 5 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2021 | 542 | 0.030 |
Why?
|
| Ecology | 1 | 2016 | 5 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2016 | 10 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2016 | 21 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1998 | 380 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2016 | 20 | 0.030 |
Why?
|
| Fallopian Tubes | 2 | 1997 | 2 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 64 | 0.030 |
Why?
|
| Catheterization, Peripheral | 1 | 1996 | 2 | 0.030 |
Why?
|
| Drug Compounding | 1 | 2016 | 22 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 1996 | 15 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 409 | 0.030 |
Why?
|
| Internal-External Control | 1 | 1995 | 1 | 0.030 |
Why?
|
| Personality Inventory | 1 | 1995 | 1 | 0.030 |
Why?
|
| Temperature | 1 | 2016 | 56 | 0.030 |
Why?
|
| Pain Measurement | 1 | 1995 | 15 | 0.030 |
Why?
|
| Seasons | 1 | 2016 | 149 | 0.030 |
Why?
|
| Equipment and Supplies | 1 | 2015 | 3 | 0.030 |
Why?
|
| Health Information Systems | 1 | 2015 | 2 | 0.030 |
Why?
|
| Health Planning | 1 | 2015 | 13 | 0.030 |
Why?
|
| Asia | 1 | 2015 | 70 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1997 | 186 | 0.030 |
Why?
|
| Leadership | 1 | 2015 | 20 | 0.030 |
Why?
|
| Streptococcus agalactiae | 1 | 1997 | 197 | 0.030 |
Why?
|
| Lamivudine | 1 | 2015 | 86 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 1992 | 63 | 0.030 |
Why?
|
| Community Participation | 1 | 2015 | 42 | 0.030 |
Why?
|
| Lopinavir | 1 | 2015 | 137 | 0.030 |
Why?
|
| Ritonavir | 1 | 2015 | 137 | 0.030 |
Why?
|
| Health Personnel | 1 | 1997 | 229 | 0.030 |
Why?
|
| Africa South of the Sahara | 1 | 2015 | 328 | 0.030 |
Why?
|
| Catheters, Indwelling | 1 | 1994 | 3 | 0.030 |
Why?
|
| Needles | 1 | 1994 | 12 | 0.030 |
Why?
|
| Africa | 1 | 2015 | 360 | 0.030 |
Why?
|
| Amniocentesis | 1 | 1994 | 1 | 0.030 |
Why?
|
| Twins, Dizygotic | 1 | 1994 | 1 | 0.030 |
Why?
|
| Potassium Chloride | 1 | 1994 | 4 | 0.030 |
Why?
|
| Parity | 2 | 2001 | 19 | 0.030 |
Why?
|
| Internet | 1 | 2013 | 12 | 0.030 |
Why?
|
| Ultrasonography | 3 | 1997 | 77 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 1993 | 2 | 0.030 |
Why?
|
| Laparotomy | 1 | 2013 | 2 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1993 | 16 | 0.030 |
Why?
|
| Operating Tables | 1 | 2013 | 1 | 0.030 |
Why?
|
| Electrocardiography | 2 | 1983 | 35 | 0.030 |
Why?
|
| Povidone-Iodine | 1 | 1993 | 1 | 0.030 |
Why?
|
| Therapeutic Irrigation | 1 | 1993 | 4 | 0.030 |
Why?
|
| Placenta Diseases | 1 | 1993 | 5 | 0.030 |
Why?
|
| Geographic Information Systems | 1 | 2012 | 5 | 0.030 |
Why?
|
| Patient Satisfaction | 2 | 2007 | 41 | 0.030 |
Why?
|
| Communication | 1 | 2012 | 56 | 0.030 |
Why?
|
| Uterine Cervical Diseases | 1 | 1991 | 1 | 0.020 |
Why?
|
| Uterine Cervical Incompetence | 1 | 1991 | 1 | 0.020 |
Why?
|
| Dilatation | 1 | 1991 | 2 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 1991 | 12 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1996 | 61 | 0.020 |
Why?
|
| Anxiety | 1 | 1991 | 39 | 0.020 |
Why?
|
| Blood Pressure Monitors | 1 | 1991 | 1 | 0.020 |
Why?
|
| Prednisolone | 1 | 2010 | 10 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2010 | 13 | 0.020 |
Why?
|
| Intelligence | 1 | 1990 | 6 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 1990 | 16 | 0.020 |
Why?
|
| Analgesia, Epidural | 1 | 1990 | 1 | 0.020 |
Why?
|
| Erythroblastosis, Fetal | 1 | 1990 | 1 | 0.020 |
Why?
|
| Uterine Neoplasms | 2 | 1997 | 4 | 0.020 |
Why?
|
| International Classification of Diseases | 1 | 2009 | 5 | 0.020 |
Why?
|
| Preventive Health Services | 1 | 2009 | 17 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 1990 | 49 | 0.020 |
Why?
|
| Body Temperature | 1 | 1989 | 7 | 0.020 |
Why?
|
| Platelet Activating Factor | 1 | 1989 | 5 | 0.020 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 1989 | 2 | 0.020 |
Why?
|
| Administration, Rectal | 2 | 1998 | 2 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1989 | 56 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1987 | 7 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1987 | 7 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 1987 | 33 | 0.020 |
Why?
|
| Cicatrix | 1 | 1987 | 1 | 0.020 |
Why?
|
| Reoperation | 1 | 1987 | 8 | 0.020 |
Why?
|
| Head | 1 | 1987 | 8 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 1987 | 59 | 0.020 |
Why?
|
| Food Deprivation | 1 | 2007 | 1 | 0.020 |
Why?
|
| Water Deprivation | 1 | 2007 | 1 | 0.020 |
Why?
|
| Teaching Materials | 1 | 2007 | 2 | 0.020 |
Why?
|
| Enema | 1 | 2007 | 3 | 0.020 |
Why?
|
| Self Medication | 1 | 1987 | 3 | 0.020 |
Why?
|
| Vulva | 1 | 1987 | 2 | 0.020 |
Why?
|
| Uterine Prolapse | 1 | 1987 | 3 | 0.020 |
Why?
|
| Coitus | 1 | 1987 | 15 | 0.020 |
Why?
|
| HLA Antigens | 1 | 1987 | 50 | 0.020 |
Why?
|
| Wound Healing | 1 | 1987 | 24 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 43 | 0.020 |
Why?
|
| Peru | 1 | 2006 | 8 | 0.020 |
Why?
|
| Vietnam | 1 | 2006 | 11 | 0.020 |
Why?
|
| India | 1 | 2006 | 60 | 0.020 |
Why?
|
| Violence | 1 | 2007 | 68 | 0.020 |
Why?
|
| Cisapride | 1 | 1986 | 1 | 0.020 |
Why?
|
| Placentation | 1 | 1986 | 2 | 0.020 |
Why?
|
| Nurse Midwives | 1 | 1985 | 1 | 0.020 |
Why?
|
| Attitude | 1 | 1985 | 12 | 0.020 |
Why?
|
| Electromyography | 1 | 1985 | 1 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 1985 | 2 | 0.020 |
Why?
|
| Sheep | 1 | 1985 | 9 | 0.020 |
Why?
|
| Electroencephalography | 1 | 1985 | 9 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 1985 | 14 | 0.020 |
Why?
|
| Consumer Behavior | 1 | 1985 | 20 | 0.020 |
Why?
|
| Oxygen | 1 | 1985 | 25 | 0.020 |
Why?
|
| Fallopian Tube Patency Tests | 2 | 1997 | 2 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2004 | 30 | 0.010 |
Why?
|
| Movement | 1 | 1983 | 5 | 0.010 |
Why?
|
| Observer Variation | 1 | 2003 | 15 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 1983 | 10 | 0.010 |
Why?
|
| Titrimetry | 1 | 2003 | 2 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 25 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1983 | 2 | 0.010 |
Why?
|
| Focus Groups | 1 | 2004 | 180 | 0.010 |
Why?
|
| Diarrhea | 1 | 2003 | 76 | 0.010 |
Why?
|
| Disposable Equipment | 1 | 1982 | 2 | 0.010 |
Why?
|
| Endometrium | 1 | 1982 | 3 | 0.010 |
Why?
|
| Mullerian Ducts | 1 | 1981 | 1 | 0.010 |
Why?
|
| Pericarditis | 1 | 1979 | 4 | 0.010 |
Why?
|
| Pericarditis, Tuberculous | 1 | 1979 | 8 | 0.010 |
Why?
|
| Progesterone | 1 | 1998 | 5 | 0.010 |
Why?
|
| Placebos | 1 | 1998 | 44 | 0.010 |
Why?
|
| Abnormalities, Multiple | 1 | 1998 | 4 | 0.010 |
Why?
|
| Intensive Care, Neonatal | 1 | 1998 | 4 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1998 | 40 | 0.010 |
Why?
|
| Leiomyoma | 1 | 1997 | 4 | 0.010 |
Why?
|
| Lipid Peroxides | 1 | 1997 | 6 | 0.010 |
Why?
|
| Ethics, Medical | 1 | 1997 | 11 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 1997 | 55 | 0.010 |
Why?
|
| Research | 1 | 1997 | 65 | 0.010 |
Why?
|
| Equipment Failure | 1 | 1996 | 13 | 0.010 |
Why?
|
| Dopamine | 1 | 1996 | 7 | 0.010 |
Why?
|
| Epinephrine | 1 | 1996 | 9 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1996 | 13 | 0.010 |
Why?
|
| Aged | 1 | 1979 | 1650 | 0.010 |
Why?
|
| Fathers | 1 | 1993 | 9 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 1993 | 26 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1993 | 61 | 0.010 |
Why?
|
| Absorption | 1 | 1993 | 6 | 0.010 |
Why?
|
| Radiography | 1 | 1993 | 80 | 0.010 |
Why?
|
| Middle Aged | 1 | 1979 | 3425 | 0.010 |
Why?
|
| Plastics | 1 | 1990 | 1 | 0.010 |
Why?
|
| Bupivacaine | 1 | 1990 | 1 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1990 | 2 | 0.010 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 1990 | 2 | 0.010 |
Why?
|
| Congenital Abnormalities | 1 | 1989 | 7 | 0.010 |
Why?
|
| Thromboxanes | 1 | 1989 | 1 | 0.010 |
Why?
|
| Angiotensin II | 1 | 1989 | 5 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 1989 | 22 | 0.010 |
Why?
|
| Castor Oil | 1 | 1987 | 1 | 0.000 |
Why?
|
| Phytotherapy | 1 | 1987 | 6 | 0.000 |
Why?
|